23.12.2024 07:00 | STX | Results of RetailBook Offer | RNS |
17.12.2024 13:37 | STX | UK shareholder meetings calendar - next 7 days | Alliance |
06.12.2024 14:35 | STX | Shield Therapeutics to raise USD10.0 million via AOP subscription | Alliance |
06.12.2024 11:31 | STX | RetailBook Offer | RNS |
06.12.2024 11:30 | STX | Subscription by AOP Health to raise US$10 million | RNS |
21.11.2024 14:22 | STX | Shield Therapeutics shares up on strong October sales | Alliance |
21.11.2024 11:15 | STX | Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven | EQS |
21.11.2024 07:00 | STX | Business Update | RNS |
11.11.2024 14:00 | STX | Hardman & Co Video Event: Shield Therapeutics (STX) Investor Forum | EQS |
29.10.2024 14:34 | STX | Shield Therapeutics shares slide as it expands financing arrangement | Alliance |
29.10.2024 07:00 | STX | Q3 Trading Update | RNS |
25.09.2024 07:00 | STX | Results from Phase 3 paediatric study | RNS |
11.09.2024 12:25 | STX | Hardman & Co Research on Shield Therapeutics (STX): Focusing on successful execution | EQS |
04.09.2024 11:39 | STX | Shield Therapeutics revenue triples, but cost rises widen annual loss | Alliance |
04.09.2024 11:06 | STX, ROCK | AIM WINNERS & LOSERS: Rockfire Resources hails Molaoi resource upgrade | Alliance |
04.09.2024 07:00 | STX | Interim results | RNS |
28.08.2024 15:52 | STX, POLX, HFG | UK earnings, trading statements calendar - next 7 days | Alliance |
27.08.2024 19:34 | MLVN, TIME, GDP | TRADING UPDATES: Shield Therapeutics lands Canada win; RUA revenue up | Alliance |
27.08.2024 07:00 | STX | ACCRUFeR® Approved by Health Canada | RNS |
14.08.2024 07:00 | STX | Notice of interim results | RNS |
26.07.2024 15:27 | AZN, STX, TTG | EXECUTIVE CHANGES: Morgan Advanced Materials picks senior director | Alliance |
24.07.2024 07:01 | STX | Unaudited Q2 2024 Trading Update | RNS |
24.07.2024 07:00 | STX | Directorate Change | RNS |
03.07.2024 16:26 | BIRG, LLOY, ARK | EARNINGS AND TRADING: ActiveOps makes profit; Contango gets investment | Alliance |
03.07.2024 07:00 | STX | $5.7m Milestone Monetization Agreement with AOP | RNS |
20.06.2024 16:25 | STX | Results of 2024 Annual General Meeting | RNS |
28.05.2024 20:32 | GAL, ORCP, BMV | TRADING UPDATES: NetScientific backs Wanda; Inspirit Energy wins deal | Alliance |
28.05.2024 07:00 | STX | New Drug Application for Accrufer® in South Korea | RNS |
23.05.2024 07:15 | STX | Hardman & Co: Shield Therapeutics (STX): Cash management is key | EQS |
10.05.2024 15:30 | STX | Audited results for the year ended 31 Dec 2023 | RNS |
30.04.2024 19:54 | TAND, IGE, CHL | EARNINGS AND TRADING: Software Circle & Beximco report higher revenue | Alliance |
30.04.2024 07:00 | STX | Business Update for Q1 2024 | RNS |
23.04.2024 14:26 | WTB, ROR, SAFE | UK earnings, trading statements calendar - next 7 days | Alliance |
16.04.2024 07:00 | STX | Notice of Results | RNS |
21.02.2024 12:36 | STX | Shield Therapeutics sinks as strong performance marred by data issues | Alliance |
21.02.2024 07:00 | STX | Unaudited Full Year Trading Update | RNS |
09.01.2024 11:33 | STX | IN BRIEF: Shield Therapeutics hires former Akili leader as new CFO | Alliance |
09.01.2024 07:00 | STX | Appointment of new Chief Financial Officer | RNS |
07.12.2023 15:31 | COM, IGP, WSP | TRADING UPDATES: Comptoir opens restaurant; Intercede wins contract | Alliance |
07.12.2023 07:00 | STX | Q3 2023 U.S. Commercial Highlights | RNS |
27.11.2023 17:24 | STX | PDMR Transaction Notification | RNS |
15.11.2023 07:30 | STX | Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team | EQS |
20.10.2023 11:45 | STX | Abstract to be presented at Healthcare Conference | Reach |
12.10.2023 11:14 | STX | IN BRIEF: Shield Therapeutics Chief Financial Officer Rudolf to leave | Alliance |
12.10.2023 10:27 | WNWD, NBB, STX | AIM WINNERS & LOSERS: Windward sees high contracting activity levels | Alliance |
12.10.2023 07:00 | STX | Chief Financial Officer Transition | RNS |
03.10.2023 17:14 | STX, AML, ANGS | TRADING UPDATES: Aston Martin CEO ups stake; Alkemy's lithium deal | Alliance |
03.10.2023 15:00 | STX | Result of REX Retail Offer | RNS |
03.10.2023 14:29 | STX | Shield Therapeutics completes USD20 million SWK financing | Alliance |
03.10.2023 07:00 | STX | Block listing Interim Return | RNS |
03.10.2023 07:00 | STX | Completion of SWK Financing | RNS |
28.09.2023 14:54 | STX | UPDATE: Shield Therapeutics completes GBP5 million share placing | Alliance |
28.09.2023 12:50 | STX | Successful completion of US$6.1m Equity Fundraise | RNS |
28.09.2023 11:30 | STX | Shield Therapeutics raises funds for US sales push as loss narrows | Alliance |
28.09.2023 07:02 | STX | REX Retail Offer | RNS |
28.09.2023 07:01 | STX | $20m secured debt facility &proposed equity raise | RNS |
28.09.2023 07:00 | STX | Interim results update and business update | RNS |
21.09.2023 15:48 | XLM, TRLS, SBDS | UK earnings, trading statements calendar - next 7 days | Alliance |
06.09.2023 20:33 | STX | IN BRIEF: Shield Therapeutics changes reporting currency to US dollars | Alliance |
06.09.2023 07:00 | STX | Notice of Results and Change in reporting currency | RNS |
25.07.2023 09:45 | STX | Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering | EQS |
24.07.2023 14:27 | JUP, STX | Holding(s) in Company | RNS |
20.07.2023 11:43 | STX | IN BRIEF: Shield Therapeutics prescription orders up in first quarter | Alliance |
20.07.2023 07:00 | STX | Business Update and U.S. Q2 2023 Highlights | RNS |
28.06.2023 17:30 | STX | Results of 2023 Annual General Meeting | RNS |
21.06.2023 15:43 | ZED, WSG, W7L | UK shareholder meetings calendar - next 7 days | Alliance |
16.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
15.06.2023 16:35 | STX | Lapse of Offer | RNS |
15.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
15.06.2023 07:00 | STX | Acceptance Level Update | RNS |
14.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
14.06.2023 07:00 | STX | Acceptance Level Update | RNS |
13.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
13.06.2023 07:00 | STX | Acceptance Level Update | RNS |
12.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |